佐力药业 reported revenue of ¥1.76B for the period ended 2026-06-30, +10.3% year on year. Net income was ¥0.38B, a 21.5% net margin on a 62.6% gross margin. The largest revenue line is 乌灵系列 at 50% of the total. Free cash flow for the period was ¥0.13B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.76B | +10.3% |
| Gross profit | ¥1.10B | — |
| Operating income | ¥0.45B | — |
| Net income | ¥0.38B | +0.0% |
| Gross margin | 62.6% | Net margin 21.5% |
| Revenue Q/Q | -3.5% | — |
| Segment | Revenue | Share |
|---|---|---|
| 乌灵系列 | ¥0.89B | 50.4% |
| 中药饮片 | ¥0.30B | 17.1% |
| 其他 | ¥0.25B | 14.1% |
| 百令系列 | ¥0.13B | 7.2% |
| 多微系列 | ¥0.10B | 5.7% |
| 中药配方颗粒 | ¥0.10B | 5.5% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.66B | 37.4% |
| R&D | ¥0.02B | 1.3% |
| SG&A | ¥0.64B | 36.5% |
| Tax & other | ¥0.07B | 3.9% |
| Item | Amount |
|---|---|
| Total assets | ¥5.20B |
| Total liabilities | ¥1.81B |
| Shareholders' equity | ¥3.38B |
| Equity / assets | 65.1% |
| Operating cash flow | ¥0.15B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥0.13B |
| Cash conversion (OCF / net income) | 61% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
捷成股份 ・ 东软载波 ・ 力源信息 ・ 通裕重工 ・ 永清环保 ・ 国投智能 ・ 神农种业 ・ 维尔利 ・ 潜能恒信 ・ 科德教育 ・ 佳士科技 ・ 福安药业
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies